A Randomized, Double-Blind, 12-week, Parallel Group, Placebo-Controlled Study of the Efficacy and Safety of RO4917523 in Patients with Fragile X Syndrome

ID Number 12-0812

Principal Investigator(s)
Alexander Kolevzon

Department(s) or Division(s)


This is a study to examine the efficacy and safety of RO4917523, an experimental oral medication that is an mGlur5 receptor antagonist in subjects aged 14-17 with Fragile X syndrome. All subjects will receive 12 weeks of treatment with RO4917523 or placebo in a double-blind, placebo-controlled, parallel group study design. 

Contact Information
Stacey Lurie
(212) 241-3692

Recruiting Patients: Yes